161 related articles for article (PubMed ID: 37349129)
1. Response to "
Aizenbud L; Schoenfeld DA; Caulfield JI; Mann JE; Austin MR; Perdigoto AL; Herold KC; Kluger HM
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349129
[No Abstract] [Full Text] [Related]
2.
Meng XY
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277194
[No Abstract] [Full Text] [Related]
3. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.
Caulfield JI; Aizenbud L; Perdigoto AL; Meffre E; Jilaveanu L; Michalek DA; Rich SS; Aizenbud Y; Adeniran A; Herold KC; Austin MR; Kluger H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898736
[TBL] [Abstract][Full Text] [Related]
4. Re: Germline Variants Associated with Toxicity to Immune Checkpoint Blockade.
Jones JO; Mitchell TJ; Stewart GD
Eur Urol; 2023 Dec; 84(6):597. PubMed ID: 36964039
[No Abstract] [Full Text] [Related]
5. Beyond probiotics: postbiotics sensitize cancer cells to immune checkpoint inhibitors.
Liu W; Pi Z; Mao W
Trends Cancer; 2024 Jan; 10(1):5-7. PubMed ID: 38101956
[TBL] [Abstract][Full Text] [Related]
6. Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.
Montaudié H; Beranger GE; Reinier F; Nottet N; Martin H; Picard-Gauci A; Troin L; Ballotti R; Passeron T
Pigment Cell Melanoma Res; 2021 Sep; 34(5):978-983. PubMed ID: 33449414
[TBL] [Abstract][Full Text] [Related]
7. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.
Yoshihama S; Cho SX; Yeung J; Pan X; Lizee G; Konganti K; Johnson VE; Kobayashi KS
Sci Rep; 2021 Feb; 11(1):3258. PubMed ID: 33547395
[TBL] [Abstract][Full Text] [Related]
8. Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
Trabelsi Grati O; Zemoura L; Nhy C; Daniel C; Melaabi S; Callens C; Gauthier Villars M; Bièche I; Girard N
Lung Cancer; 2022 Dec; 174():186-187. PubMed ID: 36156246
[TBL] [Abstract][Full Text] [Related]
9. HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.
Ivanova M; Shivarov V
Int J Immunogenet; 2021 Apr; 48(2):193-200. PubMed ID: 33112034
[TBL] [Abstract][Full Text] [Related]
10. Multitumor Case Series of Germline
Kinget L; Bechter O; Punie K; Debruyne PR; Brems H; Clement P; Roussel E; Van Herck Y; Albersen M; Baldewijns M; Schöffski P; Beuselinck B
Curr Oncol; 2021 Aug; 28(5):3227-3239. PubMed ID: 34449592
[TBL] [Abstract][Full Text] [Related]
11. Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab.
Kiyomiya M; Fukuda K; Shimazu K; Yoshida T; Taguchi D; Shinozaki H; Nanjyo H; Shibata H
Jpn J Clin Oncol; 2023 Mar; 53(3):270-274. PubMed ID: 36484308
[TBL] [Abstract][Full Text] [Related]
12. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
14. Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies.
Chen M; Hu S; Li Y; Jiang TT; Jin H; Feng L
Signal Transduct Target Ther; 2020 Nov; 5(1):270. PubMed ID: 33214545
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
16. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
[TBL] [Abstract][Full Text] [Related]
17. Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.
Catalano C; da Silva Filho MI; Frank C; Jiraskova K; Vymetalkova V; Levy M; Liska V; Vycital O; Naccarati A; Vodickova L; Hemminki K; Vodicka P; Weber ANR; Försti A
PLoS One; 2018; 13(2):e0192385. PubMed ID: 29408916
[TBL] [Abstract][Full Text] [Related]
18. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
Shukla A; Cloutier M; Appiya Santharam M; Ramanathan S; Ilangumaran S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671123
[TBL] [Abstract][Full Text] [Related]
19. Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.
Chhibber A; Huang L; Zhang H; Xu J; Cristescu R; Liu X; Mehrotra DV; Shen J; Shaw PM; Hellmann MD; Snyder A
Immunity; 2022 Jan; 55(1):56-64.e4. PubMed ID: 34986342
[TBL] [Abstract][Full Text] [Related]
20. Rethinking immune checkpoint blockade: 'Beyond the T cell'.
Liu X; Hogg GD; DeNardo DG
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
